Director/PDMR Shareholding

RNS Number : 8861J

Oxford Cannabinoid Tech.Holdings

15 December 2022

 

Oxford Cannabinoid Technologies Holdings plc

Director Dealings

Oxford Cannabinoid Technologies Holdings plc ("the Company"), announces that it has been informed today that Clarissa Sowemimo-Coker, the Interim Chief Executive Officer has today purchased ordinary shares of £0.01 in the Company ("Ordinary Shares").

Director	Total number of Ordinary Shares purchased	Price per Ordinary Share	Number of Ordinary Shares held following the purchase
Clarissa Sowemimo-Coker	500,000 500,000	£0.00615 £0.00625	1,189,594

The PDMR form is set out below.

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014 (which forms part of domestic UK law pursuant to the European Union (Withdrawal) Act 2018).

The Directors of the Company accept responsibility for the content of this announcement.

Enquiries:

Oxford Cannabinoid Technologies Holdings plc Clarissa Sowemimo-Coker (Interim CEO)	[phone] [e-mail]
Cairn Financial Advisers LLP Emily Staples Jo Turner	[phone] [phone]
Axis Capital Markets Limited Kamran Hussain Richard Hutchison finnCap Ltd Geoff Nash/Fergus Sullivan Nigel Birks (ECM) Walbrook PR Limited Paul Vann/Nick Rome	[phone] [phone] [phone] [phone] [e-mail]

About Oxford Cannabinoid Technologies Holdings Plc:

Oxford Cannabinoid Technologies Holdings plc is the holding company of Oxford Cannabinoid Technologies Ltd (together the "Group"), a pharmaceutical Group developing prescription cannabinoid medicines for approval by key medicines regulatory agencies worldwide and targeting the U$ multi-billion pain market. Cannabinoids are compounds found in the cannabis plant that have been shown to have a range of therapeutic effects on the body, including pain relief. The Group has a clearly defined path to commercialisation, revenues and growth. The Group is developing drug candidates through clinical trials to gain regulatory approval (FDA/MHRA/EMA) that will enable medical professionals to prescribe them with confidence.

The Group's portfolio aims to balance risk, value and time to market, whilst ensuring market exclusivity around all its key activities. The Group's lead compound, OCT461201, is a highly potent and selective CB2 agonist and is being developed by OCTP in a solid oral dosage form. OCTP is conducting pre-clinical testing and development with a clinical trial scheduled for Q1 2023. The Group's product pipeline also uses a balanced drug product strategy that employs both natural and synthetic compounds for the treatment of rare diseases and includes chemically modified phytocannabinoids with improved drug-like characteristics and a proprietary library of cannabinoids.

OCTP operates a partnership model with external academic and commercial partners.

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014
1	Details of the person discharging managerial responsibilities/person closely associated
a.	Name	Clarissa Sowemimo-Coker
2	Reason for notification
a.	Position/Status	Interim Chief Executive Officer
b.	Initial notification/ Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a.	Name	Oxford Cannabinoid Technologies Holdings plc
b.	LEI	2138005SRWT4998BCE35
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a.	Description of the financial instrument, type of instrument Identification Code	Ordinary shares of £0.01 each GB00BMVMRB86
b.	Nature of the transaction	Acquisition of ordinary shares of £0.01 each
c.	Price(s) and volume(s)
			Price(s)	Volume(s)
			£0.00625	500,000
			£0.00615	500,000
d.	Aggregated information - Aggregated Volume - Price	1,000,000 £0.0062
e.	Date of the transaction	15th December 2022
f.	Place of the transaction	London, UK

 

END

 

 

DSHFLFSSFLLELIF